JP2017524656A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524656A5
JP2017524656A5 JP2016569651A JP2016569651A JP2017524656A5 JP 2017524656 A5 JP2017524656 A5 JP 2017524656A5 JP 2016569651 A JP2016569651 A JP 2016569651A JP 2016569651 A JP2016569651 A JP 2016569651A JP 2017524656 A5 JP2017524656 A5 JP 2017524656A5
Authority
JP
Japan
Prior art keywords
seq
therapeutic agent
agent according
fgf23 antibody
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016569651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524656A (ja
JP6808493B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/033226 external-priority patent/WO2015191312A1/en
Publication of JP2017524656A publication Critical patent/JP2017524656A/ja
Publication of JP2017524656A5 publication Critical patent/JP2017524656A5/ja
Application granted granted Critical
Publication of JP6808493B2 publication Critical patent/JP6808493B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016569651A 2014-06-09 2015-05-29 最適な骨形成のための血清リンの効果的かつ効率的な制御 Active JP6808493B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009474P 2014-06-09 2014-06-09
US62/009,474 2014-06-09
PCT/US2015/033226 WO2015191312A1 (en) 2014-06-09 2015-05-29 The effective and efficient control of serum phosphate for optimal bone formation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020204298A Division JP6993490B2 (ja) 2014-06-09 2020-12-09 最適な骨形成のための血清リンの効果的かつ効率的な制御

Publications (3)

Publication Number Publication Date
JP2017524656A JP2017524656A (ja) 2017-08-31
JP2017524656A5 true JP2017524656A5 (https=) 2018-07-05
JP6808493B2 JP6808493B2 (ja) 2021-01-06

Family

ID=54769049

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569651A Active JP6808493B2 (ja) 2014-06-09 2015-05-29 最適な骨形成のための血清リンの効果的かつ効率的な制御
JP2020204298A Active JP6993490B2 (ja) 2014-06-09 2020-12-09 最適な骨形成のための血清リンの効果的かつ効率的な制御

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020204298A Active JP6993490B2 (ja) 2014-06-09 2020-12-09 最適な骨形成のための血清リンの効果的かつ効率的な制御

Country Status (25)

Country Link
US (5) US10639360B2 (https=)
EP (3) EP3845245B1 (https=)
JP (2) JP6808493B2 (https=)
KR (4) KR102947335B1 (https=)
CN (1) CN106604743A (https=)
AR (2) AR100689A1 (https=)
AU (1) AU2015275128C1 (https=)
BR (2) BR112016028567A2 (https=)
CA (1) CA2949234C (https=)
CL (1) CL2016003179A1 (https=)
CY (1) CY1124328T1 (https=)
DK (2) DK3151859T3 (https=)
ES (2) ES3040805T3 (https=)
FI (1) FI3845245T3 (https=)
HR (2) HRP20210250T1 (https=)
HU (2) HUE053271T2 (https=)
LT (2) LT3845245T (https=)
MX (2) MX381052B (https=)
PE (1) PE20170248A1 (https=)
PL (2) PL3845245T3 (https=)
PT (2) PT3845245T (https=)
RS (2) RS61443B1 (https=)
SI (2) SI3151859T1 (https=)
SM (2) SMT202500342T1 (https=)
WO (1) WO2015191312A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CN106709662B (zh) * 2016-12-30 2021-07-02 山东鲁能软件技术有限公司 一种电力设备运行工况划分方法
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
BR112021019337A2 (pt) * 2019-03-29 2021-12-07 Atarga Llc Anticorpo anti-fgf23
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
EP4676955A2 (en) * 2023-03-10 2026-01-14 Ultragenyx Pharmaceutical Inc. Human fgf23-binding antibodies with improved affinity and efficacy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
AU2005202100A1 (en) 1999-05-11 2005-06-09 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
ATE461213T1 (de) 2000-07-19 2010-04-15 Advanced Res & Tech Inst Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
EP2233571B1 (en) 2000-08-11 2012-11-07 Kyowa Hakko Kirin Co., Ltd. Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP4527982B2 (ja) * 2001-12-28 2010-08-18 協和発酵キリン株式会社 線維芽細胞増殖因子−２３に対する抗体
EP1833848A2 (en) * 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
US8158725B2 (en) 2005-08-22 2012-04-17 Bridgestone Corporation Functionalized polymers and tires therefrom
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
US9982023B2 (en) * 2011-11-15 2018-05-29 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.

Similar Documents

Publication Publication Date Title
JP2017524656A5 (https=)
JP2021050226A5 (https=)
JP2020518599A5 (https=)
FI3845245T3 (fi) Seerumin fosfaatin efektiivinen ja tehokas säätely optimaalista luunmuodostusta varten
JP2017503820A5 (https=)
IL258846B2 (en) Nicotinamide for use in the treatment and prevention of optic neuropathy
JP2015212268A5 (https=)
JP2018138603A5 (https=)
JP2012510461A5 (https=)
JP2018510132A5 (https=)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2016518387A5 (https=)
JP2021530541A5 (https=)
JP2012136541A5 (https=)
JP2017503014A5 (https=)
JP2015502346A5 (https=)
JP2013533858A5 (https=)
JP2020521797A5 (https=)
JP2016515561A5 (https=)
RU2015136392A (ru) Композиции и способы, основанные на нейтрализующих антителах, доставляемых интраназально, для улучшенной терапевтической эффективности
JP2012193216A5 (https=)
JP2020097577A5 (https=)
JP2016537338A5 (https=)
JP2015517512A5 (https=)
JP2018521086A5 (https=)